This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jointown Pharmaceutical Sets Up Joint AI Lab with Peking University's Wuhan Campus MT
Jiuzhoutong Pharmaceutical Investment Co., Ltd. announced that it expects to receive CNY 10.9100689 billion in funding from Jointown Pharmaceutical Group Co., Ltd CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jointown Pharma's Unit Gets Nod for Registration of Acarbose Tablets MT
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing IASO Biotherapeutics announced that it has received funding from Shanghai Chuanghehui Investment Management Co., Ltd., Jointown Pharmaceutical Group Co., Ltd CI
Fujian Fukang Pharmaceutical Co., Ltd. announced that it has received funding from Shaoxing Shangyu Hangzhou Bay Economic Development Zone Holding Group Co., Ltd., Jointown Pharmaceutical Group Co., Ltd CI
Jointown Pharmaceutical Group Co., Ltd announces decision of Regulatory Authority on the transaction CI
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 26, 2022. CI
Jointown Pharmaceutical Group Co., Ltd's Equity Buyback announced on April 26, 2022, has expired with 36,138,098 shares, representing 1.94% for CNY 425.67 million. CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 26, 2022. CI
Jointown Pharmaceutical Group Co., Ltd announced that it expects to receive CNY 2.33 billion in funding CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Nanjing Puguang Biotechnology Co., Ltd announced that it has received $15 million in funding from Huatai Zijin Investment Co. Ltd, Nanjing XinGong Investment Group Co., Ltd, Shanghai Wenzhou Investment Management Co., Ltd., Jointown Pharmaceutical Group Co., Ltd CI
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 26, 2022. CI
Amcare Lab announced that it has received $31 million in funding from Jointown Pharmaceutical Group Co., Ltd, Technology Financial Group, Fosun Group, K2VC, Bison Capital Asset Management, LLC, CICC Capital Management Co., Ltd. CI
Jointown Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 600 million worth of its shares. CI
Jointown Pharmaceutical Group Co., Ltd authorizes a Buyback Plan. CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Binhui Biopharm announced that it has received $47.1 million in funding from Yangtze River Pharmaceutical Co., Ltd., DiNovA Venture Capital, Ming Capital, Jointown Pharmaceutical Group Co., Ltd, Hubei Provincial High and New Industry Investment Group Co., Ltd. CI
Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Jointown Pharmaceutical Group Co., Ltd
More charts
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Company’s products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.23 CNY
Average target price
10.18 CNY
Spread / Average Target
+23.75%
Consensus
  1. Stock Market
  2. Equities
  3. 600998 Stock
  4. News Jointown Pharmaceutical Group Co., Ltd
  5. Jointown Pharmaceutical : Swiss Logistics Firm Kuehne+Nagel Partners with Jointown to Manage Vaccine Distribution in China